Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-Current Assets: 2017-2025

Historic Non-Current Assets for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $115.3 million.

  • Protagonist Therapeutics' Non-Current Assets fell 9.30% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.3 million, marking a year-over-year decrease of 9.30%. This contributed to the annual value of $12.6 million for FY2024, which is 486.64% up from last year.
  • Protagonist Therapeutics' Non-Current Assets amounted to $115.3 million in Q3 2025, which was down 0.19% from $115.5 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Non-Current Assets registered a high of $136.3 million during Q1 2025, and its lowest value of $1.7 million during Q1 2024.
  • In the last 3 years, Protagonist Therapeutics' Non-Current Assets had a median value of $12.6 million in 2024 and averaged $51.6 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 87.78% in 2022, then soared by 7,809.00% in 2025.
  • Over the past 5 years, Protagonist Therapeutics' Non-Current Assets (Quarterly) stood at $7.0 million in 2021, then plummeted by 33.52% to $4.6 million in 2022, then plummeted by 53.55% to $2.1 million in 2023, then soared by 486.64% to $12.6 million in 2024, then fell by 9.30% to $115.3 million in 2025.
  • Its Non-Current Assets stands at $115.3 million for Q3 2025, versus $115.5 million for Q2 2025 and $136.3 million for Q1 2025.